Development of a Miniaturized 384-Well High Throughput Screen for the Detection of Substrates of Cytochrome P450 2D6 and 3A4 Metabolism

The identification of a large number of biologically active chemical entities during high throughput screening (HTS) necessitates the incorporation of new strategies to identify compounds with druglike properties early during the lead prioritization and development process. One of the major steps in lead prioritization is the assessment of drug metabolism mediated by the cytochrome P450 (CYP) enzymes to evaluate the potential drug-drug interactions. CYP2D6 and CYP3A4 comprise the main human CYP enzymes involved in drug metabolism. The recent availability of specific CYP cDNA expression systems and the development of specific fluorescent probes have accelerated the ability to develop robust in vitro assays in HTS format. The aim of this study was to optimize conditions for the CYP2D6 and CYP3A4 HTS assays and subsequently adapt those assays to a miniaturized 384-well format. Assay conversion to a miniaturized format presents certain difficulties, such as robustness of the signal and of compound delivery. Thus the assay optimization involved the comparison of different substrates to identify those most suitable for use in a miniaturized format. Because of current technical limitations in liquid dispensing of nanoliter volumes, assay sensitivity to organic solvents also provides a main concern during assay miniaturization. Therefore, compound activity from redissolved dry films and from DMSO stocks directly delivered into assay buffer was compared. The data indicate that compound activity was comparable in both formats. The data support the conclusion that CYP2D6 and CYP3A4 in vitro metabolism assays can be successfully performed in 384-well plate format and the substrate potencies, as evaluated by the IC50 values, determined.

[1]  A. Parkinson.  An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials , 1996, Toxicologic pathology.

[2]  J. Smart,et al.  Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. , 1998, Toxicology letters.

[3]  R. E. White,et al.  High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. , 2000, Annual review of pharmacology and toxicology.

[4]  S. Venkatesh,et al.  Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.

[5]  R. Plumb,et al.  Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. , 1998, Rapid communications in mass spectrometry : RCM.

[6]  D A Smith,et al.  Pharmacokinetics and metabolism in early drug discovery. , 1999, Current opinion in chemical biology.

[7]  B. Salomon,et al.  Development of a V79 cell line expressing human cytochrome P450 2D6 and its application as a metabolic screening tool. , 1997, Environmental toxicology and pharmacology.

[8]  M H Tarbit,et al.  High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. , 1998, Current opinion in chemical biology.

[9]  Kevin R. Oldenburg,et al.  Miniaturization of a Mammalian Cell-Based Assay: Luciferase Reporter Gene Readout in a 3 Microliter 1536-Well Plate , 1999, Journal of biomolecular screening.

[10]  R J Riley,et al.  Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[11]  F. Guengerich,et al.  Differential inhibition of individual human liver cytochromes P-450 by cimetidine. , 1991, Gastroenterology.

[12]  L. M. Holland,et al.  The effect of application frequency on epidermal carcinogenesis assays. , 1982, Toxicology.

[13]  B. W. Penman,et al.  Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. , 1997, Analytical biochemistry.

[14]  K. R. Oldenburg,et al.  Chapter 30 – Current and Future Trends in High Throughput Screening for Drug Discovery , 1998 .

[15]  B. Fichtl,et al.  Binding of drugs to tissues. , 1983, Drug metabolism reviews.

[16]  N. Olejnik,et al.  Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  E E Swartzman,et al.  A homogeneous and multiplexed immunoassay for high-throughput screening using fluorometric microvolume assay technology. , 1999, Analytical biochemistry.

[18]  S. Wrighton,et al.  Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[19]  J. Broach,et al.  New assay technologies for high-throughput screening. , 1998, Current opinion in chemical biology.

[20]  U. Haupts,et al.  Homogeneous fluorescence readouts for miniaturized high-throughput screening: theory and practice. , 1999, Drug discovery today.

[21]  D. Greenblatt,et al.  Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. , 1999, Drug metabolism reviews.

[22]  W. Jaeger,et al.  Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.

[23]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[24]  I. Kariv,et al.  Analysis of protein-peptide interaction by a miniaturized fluorescence polarization assay using cyclin-dependent kinase 2/cyclin E as a model system. , 1999, Analytical biochemistry.

[25]  M K Bayliss,et al.  High-throughput pharmacokinetics: cassette dosing. , 1999, Current opinion in drug discovery & development.

[26]  A. Nomeir,et al.  Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies , 1998 .

[27]  G M Pacifici,et al.  Methods of Determining Plasma and Tissue Binding of Drugs , 1992, Clinical pharmacokinetics.

[28]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[29]  R. Obach,et al.  Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.